BioSpace News Archive

Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced the appointment of two new members to the Company’s Board of Directors, effective February 1, 2020.

New Orders and Production Growing; Employment Contracting; Supplier Deliveries Slowing at Slower Rate; Backlog Contracting; Raw Materials Inventories Contracting; Customers’ Inventories Too Low; Prices Increasing; Exports and Imports Growing

This new study by The Beljanski Foundation on reducing BPH with the Pao pereira extract is published in the high-profile journal Scientific Reports on Nature.com

Menlo Park, Calif.-Based Foundation Receives Key Funding to Support Goal to Cure Genetic Form of Epilepsy in Children

The California Pharmacists Association’s Board of Trustees announced that Susan Bonilla has been appointed Chief Executive Officer of the nation’s largest, statewide pharmacy association representing the profession and all pharmacy practice settings.

CG Life, an integrated marketing and communications agency focused on life science and healthcare, has advanced three members of its team to senior positions with increased responsibility in digital marketing, marketing strategy and business development.

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today it has completed the previously announced acquisition of Aevi Genomic Medicine (NASDAQ: GNMX) in an all-stock transaction valued at approximately $15.6 million at close

Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced an underwritten public offering of its common stock.

Veeva Systems will announce financial results for its fourth quarter and full fiscal year which ended January 31, 2020 after market close on March 3, 2020.

QIAGEN N.V. announced the CE-marking and launch of its therascreen® PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation.